Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: A multicentre, open-label study in Spain

Drug Safety

Volumn 32, Issue 1, 2009, Pages 33-42

  Valero, Antonio ^a   De La Torre, Fernando ^b   Castillo, José Antonio ^c   Rivas, Pilar ^d   Del Cuvillo, Alfonso ^e   Antépara, Ignacio ^f   Borja, Javier ^g   Donado, Esther ^g   Molà, Oriol ^g   Izquierdo, Iñaki ^g  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^c CAP I   (Spain)

^d HOSPITAL DE VILADECANS   (Spain)

^e Clinica Dr Lobaton   (Spain)

^f HOSPITAL DE BASURTO   (Spain)

^g J Uriach y Compania   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RUPATADINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALLERGIC RHINOCONJUNCTIVITIS; ARTICLE; BACKACHE; CATARRH; CHILD; CLINICAL TRIAL; COMMON COLD; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ECG ABNORMALITY; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INFLUENZA; KNEE PAIN; LOW BACK PAIN; MALE; MULTICENTER STUDY; MYALGIA; ODYNOPHAGIA; OPEN STUDY; PATIENT COMPLIANCE; PERENNIAL RHINITIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; RESPIRATORY TRACT DISEASE; RHINOCONJUNCTIVITIS; SCHOOL CHILD; SIDE EFFECT; SKIN CRUST; SKIN DISEASE; SKIN SCAB; SOMNOLENCE; SORE THROAT; SPAIN; SYMPTOM;

ADOLESCENT; ADULT; AGED; CHILD; CYPROHEPTADINE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RHINITIS, ALLERGIC, PERENNIAL; SPAIN; TIME FACTORS; YOUNG ADULT;

EID: 58149347350     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932010-00003     Document Type: Article

References (32)

1. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl.): S147-334
2. Dykewicz MS, Fineman S. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478-518
3. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82: 233-48
4. Gelfand EW, Plaut M, Washington T, et al. Current trends in allergic reactions: a multidisciplinary approach to patient management. Interdisciplinary Med 2003; 5: 1-12
5. Bousquet J, Annesi-Maesano I, Carat F, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35: 728-32
6. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006; 117: 158-62
7. Van Hoecke H, Vastesaeger N, Dewulf L, et al. Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy 2006; 61: 705-11
8. Baroody FM. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 2003; 128: 616-31
9. Schoenwetter WF, Dupclay L, Appajosyula S, et al. Economic impact and quality of life burden of allergic rhinitis. Curr Med Res Opin 2004; 20: 305-17
10. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000; 85: 338-47
11. Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002; 57: 287-96
12. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006; 7: 1989-2001
13. Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem 2004; 4: 923-33
14. Piwinski JJ, Wong JK, Green MJ, et al. Dual antagonists of platelet activating factor and histamine: identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta-[1,2-b]pyridin- 11-ylidene) piperidines. J Med Chem 1991; 34: 457-61
15. Page CP. The role of platelet activating factor in allergic respiratory disease. Br J Clin Pharmacol 1990; 30 Suppl. 1: 99-106S
16. Prescott SM, Zimmerman GA, McIntyre TM. The production of platelet-activating factor by cultured human endothelial cells: regulation and function. In: Synder F, editor. Platelet activating factor and related lipid mediators. New York: Plenum Press, 1987: 323-40
17. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007; 67: 457-74
18. Donado E, García O, Pérez I, et al. Cardiac safety of rupatadine according to the new ICH guideline: a thorough QT/QTc study [abstract no. 760]. XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10-14; Vienna
19. Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 Sep; 33 (9): 1305-24
20. DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999; 21 (2): 281-95
21. European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Medicinal Products for Human Use: guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. London: Committee for Medicinal Products from EMEA, 2005
22. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Topic E1A note for guidance: population exposure: the extent of population exposure to assess clinical safety. Geneva: ICH, 1995
23. Meyboom RHB, Hekster YA, Egberts ACG, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: 374-89
24. International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting. Geneva: ICH, 1994 Oct
25. Report of CIOMS Working Group V. Current challenges in pharmacovigilance: pragmatic approaches. Geneva: CIOMS, 2001
26. Ulbrich E, Nowak H. Long-term multicentric study with azelastine in patients with asthma. Arzneimittelforschung 1990 Nov; 40 (11): 1225-30
27. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003; 111: S835-42
28. Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc 2000; 21: 15-20
29. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allegry Clin Immunol 2004; 114: 838-44
30. Rinne J, Simola M, Malmberg H, et al. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002; 109: 426-32
31. Scadding GK, Tasman AJ, Murrieta-Aguttes M, et al. Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis: Riperex Study Group. J Int Med Res 1999; 27: 273-85
32. Nathan RA, Mason J, Bernstein DI, et al. Long-term tolerability of fexofenadine in healthy volunteers. Clin Drug Invest 1999; 18: 317-28